Novartis, Antares stars align in cancer deal that could top $1.9B

Novartis Forges $1.9B Oncology Discovery Deal with Antares

Novartis and Antares Therapeutics have entered a collaboration to develop small molecule oncology therapies. Novartis will provide $105 million in upfront cash and up to $1.8 billion in potential milestone payments. Antares Therapeutics, a Scorpion Therapeutics spinout, will lead all research activities, utilizing its discovery engine to target historically undruggable targets. The agreement grants Novartis the option to advance programs, aiming to create new precision medicines for hard-to-treat cancers by combining Antares' innovative platform with Novartis' development capabilities.

• Novartis has committed a significant financial investment in Antares Therapeutics, including an initial $105 million cash payment and potential milestone payments reaching up to $1.8 billion. This substantial deal, potentially totaling $1.9 billion, underscores Novartis' strategic focus on expanding its oncology pipeline through external innovation and Antares' value in the precision medicine space.
• Antares Therapeutics will spearhead all research efforts, leveraging its advanced discovery engine. This platform integrates cutting-edge methodologies such as covalent drug design, chemical proteomics, structure-driven computation, and machine learning, specifically designed to unlock and develop small molecule therapies against challenging, historically undruggable targets in oncology.
• The collaboration is strategically designed to accelerate the translation of scientific discoveries into transformative therapies for patients. By combining Antares' specialized discovery capabilities with Novartis' extensive development expertise and global reach, the partnership aims to overcome limitations in targeting complex cancers and deliver first-in-class precision medicines more efficiently.

Novartis and Antares Partner to Unlock Undruggable Cancer Targets

Recent oncology research has identified a diverse array of novel molecular targets spanning multiple cancer types, reflecting the field's shift toward precision and mechanism-driven therapeutics. Among the most compelling emerging targets is SAG (Sensitive to Apoptosis Gene, also known as RBX2/ROC2/RNF7), a dual E3 ubiquitin ligase overexpressed across numerous human cancer tissues and positively correlated with poor patient survival. SAG functions as a catalytic subunit of both CRL5 and CRL1 complexes, driving ubiquitylation and degradation of tumor suppressor substrates; its knockdown or knockout results in tumor suppressor accumulation and inhibition of cancer cell growth. Small molecule inhibitors and PROTAC degraders targeting SAG are currently in active drug discovery. Similarly, USP7, a deubiquitinating enzyme that stabilizes oncogenic proteins and immunosuppressive factors, has yielded the structure-based lead compound OAT-4828, which demonstrated significant antileukemic activity in a syngeneic model of B-cell derived non-Hodgkin lymphoma. In pancreatic cancer, EZH2 — the catalytic component of polycomb repressive complex 2 (PRC2) — mediates epigenetic silencing via H3K27me3 trimethylation, suppressing tumor suppressors and fostering an immunosuppressive tumor microenvironment. Critically, NRF1 has been identified as the dominant driver of EZH2 overexpression, with co-expression of NRF1 and EZH2 conferring significantly greater sensitivity to EZH2 inhibitors such as GSK343 and tazemetostat, offering a potential combinatorial predictive biomarker strategy.

Immune modulation and translational regulation represent additional frontiers of therapeutic exploration. Complement component 5a receptor 1 (C5aR1), predominantly expressed by tumor-associated macrophages, has been identified as a target of citalopram through drug repurposing methodologies including global reverse gene expression profiling, drug affinity responsive target stability assay, and molecular docking; citalopram treatment enhances macrophage phagocytosis and elicits CD8⁺ T cell anti-tumor immunity in hepatocellular carcinoma. In triple-negative breast cancer, eukaryotic elongation factor 1A1 (EEF1A1) — a key mediator of peptide chain elongation — has been validated as the direct binding partner of a penicillide-derived compound (compound 2 from Penicillium sp. NBU2256) via DARTS and CETSA assays; downstream suppression of RPL27A and RPLP0 at the translational level inhibits tumor cell invasion and migration. PD-L1 continues to attract mechanistic refinement, with novel N-terphenylpicolinamide derivatives demonstrating high-affinity binding and activation of primary immune cells to enhance cancer cell elimination. MicroRNA-based targets are also gaining traction: miR-218 exhibits tumor-suppressive properties in lung cancer with an inverse correlation to tumor aggressiveness, while the miR-200 family regulates epithelial-mesenchymal transition, angiogenesis, and chemoresistance in gastrointestinal cancers, with exosomal miR-200 achieving diagnostic AUC values of up to 0.97 in pancreatic ductal adenocarcinoma.

Radiopharmaceutical and AI-accelerated approaches are further expanding the targetable landscape. CD44v6, frequently overexpressed in pancreatic ductal adenocarcinoma, has been successfully engaged by [¹⁷⁷Lu]Lu-AKIR001, a targeted radioligand that achieved in vivo tumor uptake exceeding 100 %IA/g, with complete remissions observed in 40% of xenograft-bearing mice at 12 MBq and 14% in combination with paclitaxel at 4 MBq. Building on established FDA-approved radioligand therapies — [¹⁷⁷Lu]Lu-PSMA-617 (Pluvicto®) for metastatic castration-resistant prostate cancer and [¹⁷⁷Lu]Lu-DOTA-TATE (Lutathera®) for neuroendocrine tumors — emerging radioligands targeting novel molecular pathways are being rationally combined with DNA damage response agents, including PARP inhibitors, and immunotherapies to enhance therapeutic response. Underpinning these discoveries, artificial intelligence applications are accelerating target identification by predicting protein structures, ranking disease-relevant genes, assessing target druggability, and optimizing pharmacological and physicochemical properties through virtual screening of multiplexed chemical libraries — fundamentally transforming the pace and precision of oncology drug discovery.

Antares' Engine: Decoding Cancer's Molecular Drivers

Cancer development is fundamentally a genetic disease driven by the accumulation of somatic and germline mutations that dysregulate the core machinery of cell proliferation and survival. At its foundation, carcinogenesis involves the mutational activation of proto-oncogenes and the inactivation of tumor suppressor genes — two complementary processes that collectively override physiologic growth controls. Key regulatory genes such as p53, RAS, and RAF are among the most frequently implicated; p53 in particular governs cell cycle arrest and apoptotic responses, and its loss is a hallmark of broad tumor aggressiveness. No single oncogenic lesion is sufficient to drive full malignant transformation; rather, tumors accumulate a complementary set of mutations that collectively disable checkpoint mechanisms, bypass cellular senescence, and confer genomic instability. This genomic instability — manifest as aneuploidy, chromosomal rearrangements, and hypermutability — is governed in part by mitotic checkpoint genes such as BUB1B and structural regulators like cohesin, and is thought to precede the acquisition of fully transforming mutations in critical target genes. Hereditary cancer syndromes, which account for approximately 1–8% of cancers, further illustrate this architecture: germline mutations in tumor suppressor genes such as BRCA1, BRCA2, and mismatch repair genes dramatically lower the mutational threshold required for tumor initiation.

At the molecular signaling level, cancer progression reflects a progressive disorder of intracellular and intercellular signal transduction. Multiple pathways are recurrently dysregulated, including PI3K/AKT/mTOR, MAPK/ERK, Wnt, Notch, Sonic Hedgehog (Shh), TGF-β, Hippo, and JAK-STAT signaling cascades. These pathways govern proliferation, differentiation, apoptosis resistance, and metabolic reprogramming. The Warburg effect — a metabolic shift toward aerobic glycolysis — alongside mitochondrial dysfunction involving mutations in genes encoding succinate dehydrogenase, fumarate hydratase, and isocitrate dehydrogenase, further supports tumor growth through mechanisms including pseudo-hypoxic drive via constitutive HIF-1α activation and oncometabolite accumulation. Cell cycle deregulation is central to this process: cyclins A, B, C, D1, and E; cyclin-dependent kinases (CDKs); and CDK inhibitors including p16, p21, and p27 are systematically disrupted following mitogenic stimuli, promoting neoplastic transformation. Epigenetic remodeling compounds these effects, with dysregulation of chromatin modifications driven by aberrant signaling further shaping the tumor epigenome. Non-coding RNAs — including microRNAs, long non-coding RNAs such as H19, and circular RNAs — serve as additional regulatory layers, functioning as oncogenes or tumor suppressors by modulating target gene expression at the posttranscriptional level, influencing epithelial-mesenchymal transition (EMT), and mediating drug resistance through factors such as ZEB1 and ZEB2.

Tumor progression and metastatic dissemination involve additional cellular mechanisms beyond the initiating cell. Cancer stem cells (CSCs) — a subpopulation defined by self-renewal capacity and the ability to generate differentiated progeny — are recognized as primary drivers of tumor maintenance, recurrence, and metastasis. In pancreatic cancer, for example, a CD44⁺CD24⁺ESA⁺ subpopulation representing just 0.2–0.8% of cancer cells demonstrated a 100-fold increase in tumorigenic potential, with as few as 100 cells sufficient to establish tumors in 50% of animal models. CSC behavior is regulated by developmental signaling pathways including Wnt, Notch, and Shh, as well as pluripotency transcription factors Oct-4 and Nanog. Beyond the tumor cell itself, the tumor microenvironment plays an equally critical role: tumor cells actively remodel their surrounding stroma through soluble factors, exosome-mediated intercellular communication, and suppression of immune effector functions. Mitotic kinases — including PLK1, Aurora kinases, and ROCK1 — contribute not only to aberrant cell division but also to cytoskeletal remodeling that facilitates invasion and metastatic release. Collectively, these mechanisms illustrate that cancer progression is a multistep, dynamically evolving process shaped by genetic, epigenetic, metabolic, and microenvironmental forces acting in concert.

Novartis' Strategic Moves in an Evolving Oncology Landscape

Over the past five years, the oncology treatment landscape has undergone a fundamental structural shift — moving away from histology-agnostic cytotoxic regimens toward biomarker-driven, molecularly targeted strategies. Comprehensive genomic profiling (CGP) has emerged as a standardized clinical tool: a 523-gene DNA/RNA hybrid panel demonstrated that 49% of patients harbored at least one actionable biomarker eligible for approved targeted or immunotherapy, and 53% qualified for precision oncology clinical trials. In a prospective cohort of 2,147 patients with advanced cancer, actionable targets were identified in 57% of profiled cases, and among those treated with matched targeted therapy, overall response rates reached 25% with significantly improved overall survival compared to conventional chemotherapy alone (P < .001). FDA approval patterns further reinforce this trajectory, with approved anticancer drugs showing a pooled overall survival hazard ratio of 0.70 (95% CI 0.68–0.73) versus 0.95 for non-approved agents — underscoring the measurable survival benefit concentrated in molecularly selected populations.

Immunotherapy and antibody-drug conjugates (ADCs) have jointly redefined the standard of care across multiple tumor types. Immune checkpoint inhibitors (ICIs) have expanded from the metastatic setting into early-stage disease — most notably with pembrolizumab in triple-negative breast cancer — while ICI-based combinations have been established as first-line standards in metastatic renal cell carcinoma. The tissue-agnostic FDA approval of pembrolizumab for MSI-H/dMMR solid tumors marked a pivotal regulatory precedent, decoupling treatment eligibility from tumor site. In parallel, ADCs have matured considerably, with innovations in linker technology, site-specific conjugation, and novel payloads expanding their therapeutic index across HER2, TROP-2, HER-3, and LIV-1 targets. Emerging modalities — including mRNA cancer vaccines under evaluation in pancreatic ductal adenocarcinoma, circulating tumor DNA (ctDNA)-based minimal residual disease detection, and metabolism-targeting agents such as fatty acid synthase inhibitor TVB-2640 and glutaminase inhibitor CB-839 — are progressing through clinical evaluation, with ctDNA utility most actively studied in breast, colon, and lung cancers across predominantly Phase 2 trials.

Despite these advances, critical gaps and systemic inequities persist. Global 5-year net survival is projected to remain largely stable between 2025 and 2050 at approximately 47.7%, with profound disparities by geography — ranging from 34.4% in Africa to 70.4% in Oceania — reflecting uneven access to modern therapeutics. Elderly patients remain systematically underrepresented in interventional trials, with only 1.0% of 49,273 eligible trials specifically designed for older patients, and clinically meaningful endpoints such as functional status and patient-reported outcomes used as primary endpoints in fewer than 8% of these studies. Furthermore, long-term follow-up data from Phase 3 trials reveals a pattern of attenuating effect sizes at maturity, with median hazard ratios for primary endpoints increasing from 0.66 to 0.74 upon updated analysis — a signal warranting careful interpretation of early efficacy readouts in regulatory and strategic decision-making contexts.